• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ABBV

ABBV

AbbVie Inc.

NYSEHealthcareDrug Manufacturers - GeneralUS

USD217.07

+1.67 (+0.78%)

Rating:B-

Company Profile

CEO

Robert A. Michael

IPO Date

2013-01-02

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYSE

Country

US

Market Metrics

Open

$214.80

Prev. Close

$215.40

Day Low

$213.72

Day High

$219.54

52W Low

$181.73

52W High

$244.81

Market Cap

$383.52B

Volume

5.57M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

57.9%

Avg Negative

10.9%

Avg Neutral

31.2%

News Feed

AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication

zacks.com·5/28/2026·↑ positive

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

prnewswire.com·5/27/2026·↑ positive

US FDA approves AbbVie's rare blood cancer drug

reuters.com·5/27/2026·↑ positive

How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?

zacks.com·5/27/2026·↓ negative

Prediction: These 2 Obesity Drug Stocks Could Double in 2026

fool.com·5/26/2026·↑ positive

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

prnewswire.com·5/22/2026·↑ positive

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

prnewswire.com·5/21/2026·↑ positive

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

prnewswire.com·5/21/2026·↑ positive

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

zacks.com·5/19/2026·↑ positive

Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth

zacks.com·5/18/2026·↑ positive